2019 BioCap Call for Pitches Competition Winner Announced

Bionow are delighted to announce QV Bioelectronics as the winner of the 2019 BioCap Call for Pitches Competition.

The BioCap Call for Pitches Competition is a unique opportunity for companies who are seeking investment, to present to the international life science investment community, more than 60 of whom were present at the 2019 BioCap Conference which took place on Thursday 3^rd October at Alderley Park Conference Centre.

QV Bioelectronics is developing an implanted medical device for the treatment of Glioblastoma (GBM), which is the most common primary brain cancer in adults and also has amongst the worst outcomes of any type of cancer; there is no cure and median life expectancy on the current gold standard treatment is a tragic 14 months post-diagnosis. The device utilises alternating electrical fields to produce an anti-mitotic effect on dividing cancer cells, slowing tumour growth and extending patient survival.

Head judge Gareth King from Catapult Ventures said “This year all of the pitches were particularly impressive and selecting a winner took some deliberation, but we were delighted to announce QV Bioelectronics as the winner. Chris Bullock, Founder of QV Bioelectronics gave a clear and compelling presentation that covered all they key areas needed by investors to quickly understand an investment opportunity in a short pitch. I am extremely grateful to my fellow judges Pablo Lubroth from Midven, Ben Carter from Deepbridge Capital, Claire Brown from BioCity, Emma Johnson from Catapult Ventures and Will Brooks from Downing”

BioCap is organised by Bionow in partnership with RSM, Appleyard Lees and Slater Heelis and is sponsored by Catapult Ventures, BioCity and Alderley Park.

The conference continues to successfully bring together international investors and companies and with nearly 200 delegates attended the event making this the largest and only gathering focused on life science investment in the North of England.

Geoff Davison, CEO of Bionow said “We were delighted with the quality of the pitching applications received and congratulate QV Bioelectronics. BioCap was conceived 8 years ago to increase the visibility of the impressive life sciences opportunities in the North and the number and quality of investors now involved with the event shows the quality and breadth of opportunities in the North of England”

The 8 competition finalists who pitched at the conference were:-

• MicrifluidX Ltd
• Intogral Ltd
• Nanovery Ltd
• Natantis
• Xploro Health
• Gendius Ltd
• QV Bioelectronics
• Onkolyze

About QV Bioelectronics
Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours. Compared to other diseases, the incidence of brain tumours is rare. However, the social and economic impact on society is disproportionately significant. Brain tumours result in loss of independence, suffering for patients and their loved ones, and loss of life.  A 2018 parliamentary report estimated the UK economic costs of brain tumours to be £578 million each year, the third highest of all cancers despite the small numbers of patients with these diseases.
www.qvbio.co.uk/

About Bionow
Bionow is the life-sciences membership organisation for the North of England and supports business growth, competitiveness and innovation within the biomedical and life science sectors. Bionow’s membership offering focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses.
www.bionow.co.uk

Contact:
Helen Williams, Event & Marketing Manager
helen.williams@bionow.co.uk
07714 168 020